Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation

Hee Yeon Won, Hyun Jung Min, Jin Hee Ahn, Sung Eun Yoo, Myung Ae Bae, Jeong-Ho Hong, Eun Sook Hwang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)γ, and its ligands inhibit pro-inflammatory cytokine production by immune cells, thus exerting anti-inflammatory activity. As a non-thiazolidinedione PPARγ ligand, KR62980 has anti-diabetic and anti-adipogenic activities, but its anti-inflammatory function has yet to be characterized. In this study, we investigated the functions and mechanisms of KR62980 in the activation and differentiation of CD4+ T helper (Th) cells by comparing its effects with those of a thiazolidinedione PPARγ ligand, rosiglitazone. KR62980 dose-dependently and significantly suppressed TCR-triggered Th cell proliferation by suppressing IL-2/IL-2Rα-mediated signaling. Both KR62980 and rosiglitazone suppressed IFNγ production in a dose-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980. In addition, sustained KR62980 treatment diminished Th2 cytokine production by inhibiting c-Maf expression. In vivo administration of KR62980 in a model of allergic asthma significantly attenuated eotaxin-induced eosinophil infiltration, allergic cytokine production and collagen deposition in the lung. KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node. In conclusion, a novel PPARγ ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis.

Original languageEnglish
Pages (from-to)888-896
Number of pages9
JournalBiochemical Pharmacology
Volume79
Issue number6
DOIs
Publication statusPublished - 2010 Mar 15

Fingerprint

Anti-Allergic Agents
Allergens
Inflammation
Peroxisome Proliferator-Activated Receptors
rosiglitazone
Ligands
Cytokines
Anti-Inflammatory Agents
Asthma
1-(methylimino-N-oxy)-6-(2-morpholinoethoxy)-3-phenyl-1H-indene-2-carboxylic acid ethyl ester
Th2 Cells
Goblet Cells
Interleukin-17
Nasal Mucosa
Cell proliferation
Metaplasia
Helper-Inducer T-Lymphocytes
Infiltration
Eosinophils
Gene expression

Keywords

  • Allergic airway inflammation
  • KR62980
  • PPARγ
  • Rosiglitazone
  • Th2 cell

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation. / Won, Hee Yeon; Min, Hyun Jung; Ahn, Jin Hee; Yoo, Sung Eun; Bae, Myung Ae; Hong, Jeong-Ho; Hwang, Eun Sook.

In: Biochemical Pharmacology, Vol. 79, No. 6, 15.03.2010, p. 888-896.

Research output: Contribution to journalArticle

Won, Hee Yeon ; Min, Hyun Jung ; Ahn, Jin Hee ; Yoo, Sung Eun ; Bae, Myung Ae ; Hong, Jeong-Ho ; Hwang, Eun Sook. / Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation. In: Biochemical Pharmacology. 2010 ; Vol. 79, No. 6. pp. 888-896.
@article{8aa979dfe73e4e4fb421b47a7015a92d,
title = "Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation",
abstract = "The ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)γ, and its ligands inhibit pro-inflammatory cytokine production by immune cells, thus exerting anti-inflammatory activity. As a non-thiazolidinedione PPARγ ligand, KR62980 has anti-diabetic and anti-adipogenic activities, but its anti-inflammatory function has yet to be characterized. In this study, we investigated the functions and mechanisms of KR62980 in the activation and differentiation of CD4+ T helper (Th) cells by comparing its effects with those of a thiazolidinedione PPARγ ligand, rosiglitazone. KR62980 dose-dependently and significantly suppressed TCR-triggered Th cell proliferation by suppressing IL-2/IL-2Rα-mediated signaling. Both KR62980 and rosiglitazone suppressed IFNγ production in a dose-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980. In addition, sustained KR62980 treatment diminished Th2 cytokine production by inhibiting c-Maf expression. In vivo administration of KR62980 in a model of allergic asthma significantly attenuated eotaxin-induced eosinophil infiltration, allergic cytokine production and collagen deposition in the lung. KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node. In conclusion, a novel PPARγ ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis.",
keywords = "Allergic airway inflammation, KR62980, PPARγ, Rosiglitazone, Th2 cell",
author = "Won, {Hee Yeon} and Min, {Hyun Jung} and Ahn, {Jin Hee} and Yoo, {Sung Eun} and Bae, {Myung Ae} and Jeong-Ho Hong and Hwang, {Eun Sook}",
year = "2010",
month = "3",
day = "15",
doi = "10.1016/j.bcp.2009.10.023",
language = "English",
volume = "79",
pages = "888--896",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation

AU - Won, Hee Yeon

AU - Min, Hyun Jung

AU - Ahn, Jin Hee

AU - Yoo, Sung Eun

AU - Bae, Myung Ae

AU - Hong, Jeong-Ho

AU - Hwang, Eun Sook

PY - 2010/3/15

Y1 - 2010/3/15

N2 - The ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)γ, and its ligands inhibit pro-inflammatory cytokine production by immune cells, thus exerting anti-inflammatory activity. As a non-thiazolidinedione PPARγ ligand, KR62980 has anti-diabetic and anti-adipogenic activities, but its anti-inflammatory function has yet to be characterized. In this study, we investigated the functions and mechanisms of KR62980 in the activation and differentiation of CD4+ T helper (Th) cells by comparing its effects with those of a thiazolidinedione PPARγ ligand, rosiglitazone. KR62980 dose-dependently and significantly suppressed TCR-triggered Th cell proliferation by suppressing IL-2/IL-2Rα-mediated signaling. Both KR62980 and rosiglitazone suppressed IFNγ production in a dose-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980. In addition, sustained KR62980 treatment diminished Th2 cytokine production by inhibiting c-Maf expression. In vivo administration of KR62980 in a model of allergic asthma significantly attenuated eotaxin-induced eosinophil infiltration, allergic cytokine production and collagen deposition in the lung. KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node. In conclusion, a novel PPARγ ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis.

AB - The ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)γ, and its ligands inhibit pro-inflammatory cytokine production by immune cells, thus exerting anti-inflammatory activity. As a non-thiazolidinedione PPARγ ligand, KR62980 has anti-diabetic and anti-adipogenic activities, but its anti-inflammatory function has yet to be characterized. In this study, we investigated the functions and mechanisms of KR62980 in the activation and differentiation of CD4+ T helper (Th) cells by comparing its effects with those of a thiazolidinedione PPARγ ligand, rosiglitazone. KR62980 dose-dependently and significantly suppressed TCR-triggered Th cell proliferation by suppressing IL-2/IL-2Rα-mediated signaling. Both KR62980 and rosiglitazone suppressed IFNγ production in a dose-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980. In addition, sustained KR62980 treatment diminished Th2 cytokine production by inhibiting c-Maf expression. In vivo administration of KR62980 in a model of allergic asthma significantly attenuated eotaxin-induced eosinophil infiltration, allergic cytokine production and collagen deposition in the lung. KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node. In conclusion, a novel PPARγ ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis.

KW - Allergic airway inflammation

KW - KR62980

KW - PPARγ

KW - Rosiglitazone

KW - Th2 cell

UR - http://www.scopus.com/inward/record.url?scp=74149086222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149086222&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.10.023

DO - 10.1016/j.bcp.2009.10.023

M3 - Article

C2 - 19896472

AN - SCOPUS:74149086222

VL - 79

SP - 888

EP - 896

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 6

ER -